Mesenchymal stromal cells are among the most studied and least standardized cell products in research. The same three letters cover populations from different tissues with different behavior, different expansion characteristics and different secretory profiles, which is a large part of why the literature is harder to reconcile than it should be.
What the name covers
These cells are adherent, spindle-shaped, expandable in culture, and defined by a combination of surface marker expression, plastic adherence and the ability to differentiate along several mesenchymal lineages. That definition is functional rather than molecular, which is why the field has a long-running argument about whether stem or stromal is the more honest word.
The practical consequence is that source tissue matters more than the shared name suggests. Cells from cord tissue, placenta and adult marrow satisfy the same definition and do not behave identically.
Source differences
| Source | Character | Practical notes |
|---|---|---|
| Umbilical cord tissue | Young donor cells, strong proliferative capacity | Non-invasive collection from tissue otherwise discarded |
| Placenta | Also perinatal, abundant tissue available per donation | Regional variation within the tissue affects what is isolated |
| Bone marrow | The historical reference source | Invasive collection; donor age affects proliferative capacity |
| Adipose tissue | Accessible in quantity | Different secretory profile from perinatal sources |
Perinatal sources are attractive largely because donor age is effectively zero. Proliferative capacity declines with donor age in adult-derived populations, so a cord or placental isolate typically expands further before senescence than a marrow isolate from an older donor.
Related product
Leukopak formats. Single-donor starting material, fresh or cryopreserved, with full donor documentation.
Passage number is a specification, not a detail
These cells change as they expand. Later-passage populations show reduced proliferation, altered surface marker expression, drifting differentiation capacity and a changed secretory profile. A study run at low passage and repeated at high passage may not be repeating the same experiment.
Which makes passage number something to record, specify and match between conditions rather than something noted in passing. Comparing across published work without knowing passage is one of the more common reasons results appear to conflict.
Why the secretome gets more attention than the differentiation
Early interest in these cells centred on their ability to become bone, cartilage and fat. Much of the current research interest sits instead on what they secrete, since the factors released appear to account for a substantial part of the observed effects in many models, without the cells themselves persisting or engrafting to any great extent.
That shift changes what matters in sourcing. If the secretome is the active component, then culture conditions, passage and donor source all bear directly on the result, and lot-to-lot consistency becomes the dominant practical problem.
What to establish before ordering
Source tissue, since it changes behavior. Passage at supply and remaining expansion capacity. Culture conditions used, including whether serum was involved, because that affects downstream work and any later transition. Characterization, meaning the marker profile and differentiation confirmation. Donor information. And format and grade.
OrganaBio documents mesenchymal stem cells from umbilical cord and from placenta through its perinatal program. Related perinatal material including cord blood CD34+ HSCs is covered in the cord blood guide.
Frequently asked questions
What are mesenchymal stem cells?
Adherent, spindle-shaped, culture-expandable cells defined by a combination of surface marker expression, plastic adherence and the ability to differentiate along several mesenchymal lineages. The definition is functional rather than molecular, which is why the field debates whether stem or stromal is the better term.
Does the source tissue change how they behave?
Yes. Cells from cord tissue, placenta, bone marrow and adipose tissue satisfy the same definition without behaving identically, differing in proliferative capacity, differentiation bias and secretory profile.
Why are perinatal sources often preferred?
Donor age is effectively zero, and proliferative capacity declines with donor age in adult-derived populations. A cord or placental isolate typically expands further before senescence than a marrow isolate from an older donor.
Why does passage number matter so much?
These cells change as they expand, showing reduced proliferation, altered marker expression, drifting differentiation capacity and a changed secretory profile at later passage. A study run at low passage and repeated at high passage may not be repeating the same experiment.
Why is the secretome now a bigger focus than differentiation?
Because the factors these cells release appear to account for a substantial part of observed effects in many models, without the cells persisting or engrafting extensively. That makes culture conditions, passage and donor source directly relevant to the result.
What should I ask when ordering mesenchymal cells?
Source tissue, passage at supply and remaining expansion capacity, culture conditions including whether serum was used, marker profile and differentiation confirmation, donor information, and format and grade.
Why do published mesenchymal cell results often conflict?
Because the shared name covers populations from different tissues, expanded to different passages, under different culture conditions. Comparing across studies without knowing those variables is a common source of apparent contradiction.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
